PEG-Interferon Alfa-2b and Sorafenib in Treating Patients With Unresectable or Metastatic Kidney Cancer
Status:
Terminated
Trial end date:
2009-01-01
Target enrollment:
Participant gender:
Summary
RATIONALE: PEG-interferon alfa-2b may interfere with the growth of tumor cells. Sorafenib may
stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It may
also stop the growth of kidney cancer by blocking blood flow to the tumor. Giving
PEG-interferon alfa-2b together with sorafenib may kill more tumor cells.
PURPOSE: This phase I trial is studying the side effects and best dose of PEG-interferon
alfa-2b and sorafenib in treating patients with unresectable or metastatic kidney cancer.